Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute

Drug Profile

Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute

Alternative Names: AU 011; Bel-sar; Belzupacap serotalocan; Light-activated AU-011

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aura Biosciences; National Cancer Institute (USA)
  • Developer Aura Biosciences
  • Class Antineoplastics; Drug conjugates; Immunotherapies; Phthalocyanines; Viral proteins
  • Mechanism of Action Cell death stimulants; Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveal melanoma
  • Phase I Bladder cancer
  • Preclinical Solid tumours

Most Recent Events

  • 07 Dec 2023 Phase-III clinical trials in Uveal melanoma (First-line therapy, Early-stage disease) in USA (Intraocular) (NCT06007690)
  • 06 Nov 2023 Aura Biosciences plans to submit BLA for belzupacap sarotalocan for Uveal melanoma
  • 06 Nov 2023 Aura Biosciences receives agreement from the US FDA under an Special Protocol Assessment (SPA) for the design and planned analysis of the phase III Compass trial for Uveal melanoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top